On August 28, 2026, Coherus Oncology, Inc. entered into a sales agreement with Leerink Partners LLC to offer and sell shares of its common stock through an at-the-market offering program. The company has the right to sell up to $50.0 million in aggregate gross proceeds, though it is not obligated to sell any specific amount. The agent will receive a commission of up to 3.0% of the gross proceeds from each sale. Net proceeds are intended for general corporate purposes, including working capital. This equity issuance represents a material financing event that could dilute existing shareholders and provides liquidity for near-term operations. Coherus Oncology operates in the biotechnology industry, focusing on the development and commercialization of oncology treatments.
